| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
23015 |
| Drug |
Ivosidenib |
| Brand |
Tibsovo® |
| Indication |
To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy. |
| Rapid review commissioned |
08/03/2023 |
| Rapid review completed |
17/04/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/06/2023 |
| Pre-submission consultation with Applicant |
19/09/2023 |
| Full submission received from Applicant |
21/08/2024 |
